Defence Therapeutics Announces Convertible Debenture Interest Payment

The interest settlement used shares rather than cash, while the sharing agreement delivered a third payment of $190,670.42.

Rhea-AI Summary

Defence Therapeutics (DTCFF) issued 320,000 common shares to convertible debenture holders to settle accrued and unpaid interest.

The shares satisfied $160,000 in interest on debentures dated September 15, 2025, with $2,000,000 in principal and an 8% annual interest rate. The interest shares carry a statutory hold period of four months plus one day.

Under its March 6, 2026 sharing agreement with Sorbie Bornholm LP, Defence received its third settlement of $190,670.42 on October 14, 2026, against 606,060 placement shares released to SBLP. As of October 23, 2026, 9,090,911 placement shares remained in escrow, with 15 settlement payments remaining.

2 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• Moderate point$160,000 in accrued interest settled through common shares rather than cash.
• Moderate point$190,670.42 third settlement received October 14, 2026, under the Sorbie Bornholm LP sharing agreement. 1.1% of market cap

Negative

• Moderate point320,000 common shares issued to debenture holders dilute existing shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company.

The Company announces that, in accordance with the terms and conditions of convertible debentures dated September 15, 2025, representing a principal amount of $2,000,000 and bearing interest at a rate of 8% per annum (the "Debentures"), the Company issued 320,000 common shares in the share capital of the Company (the "Interest Shares") to the holders of the Debentures in satisfaction of $160,000 in accrued and unpaid interest. Such Interest Shares are subject to a statutory hold period of four months plus one day, in accordance with applicable securities laws. For further details regarding the Debentures, see the Company's news release dated September 15, 2025, a copy of which is available under the Company's profile at www.sedarplus.ca.

The Company is also providing the update on its sharing agreement dated March 6, 2026, with Sorbie Bornholm LP, previously described in the Company's news releases of March 9 and Feb. 27, 2026. The Company has received the third settlement in the amount of $190,670.42 as of the settlement date of October 14, 2026, against 606,060 placement shares released to SBLP. As of today, 9,090,911 placement shares are held in escrow in connection with the sharing agreement, and there are 15 settlement payments remaining.

For further information:
Defence Therapeutics
Amie Phinney
President and Chief Executive Officer
P: (604) 306-8027
aphinney@defencetherapeutics.com 
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320679

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Defence Therapeutics pay its convertible debenture interest?

Defence issued 320,000 common shares to settle $160,000 in accrued and unpaid interest. The debentures are dated September 15, 2025, represent $2,000,000 in principal and bear interest at 8% per annum. The issued shares have a statutory hold period of four months plus one day.

What is the latest settlement under Defence Therapeutics' Sorbie Bornholm sharing agreement?

Defence received its third settlement of $190,670.42 on October 14, 2026, against 606,060 placement shares released to SBLP. As of October 23, 2026, 9,090,911 placement shares were held in escrow, and 15 settlement payments remained.